Trial · NCT01081795
Results by group213
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 213
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 | Topiramate (JNS019) 50 mg | Baseline | 5.9 | Standard Deviation 1.79 | Migraine attacks |
| Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 | Topiramate 100 mg | Baseline | 6.2 | Standard Deviation 2.11 | Migraine attacks |
| Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 | Placebo | Baseline | 6.6 | Standard Deviation 2.29 | Migraine attacks |
| Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 | Topiramate (JNS019) 50 mg | Change at Month 6 | -0.9 | Standard Deviation 2.50 | Migraine attacks |
| Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 | Topiramate 100 mg | Change at Month 6 | -1.2 | Standard Deviation 2.72 | Migraine attacks |
| Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 | Placebo | Change at Month 6 | -1.0 | Standard Deviation 2.42 | Migraine attacks |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate (JNS019) 50 mg | Baseline | 6.6 | Standard Deviation 2.21 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate 100 mg | Baseline | 7.0 | Standard Deviation 2.35 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Placebo | Baseline | 7.3 | Standard Deviation 2.58 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate (JNS019) 50 mg | Change at Month 1 | -0.5 | Standard Deviation 2.93 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate 100 mg | Change at Month 1 | -0.8 | Standard Deviation 3.75 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Placebo | Change at Month 1 | -0.4 | Standard Deviation 3.18 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate (JNS019) 50 mg | Change at Month 2 | -0.7 | Standard Deviation 2.82 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate 100 mg | Change at Month 2 | -1.1 | Standard Deviation 3.36 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Placebo | Change at Month 2 | -0.7 | Standard Deviation 2.83 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate (JNS019) 50 mg | Change at Month 3 | -0.9 | Standard Deviation 2.74 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate 100 mg | Change at Month 3 | -1.2 | Standard Deviation 3.27 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Placebo | Change at Month 3 | -0.9 | Standard Deviation 2.73 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate (JNS019) 50 mg | Change at Month 4 | -0.9 | Standard Deviation 2.73 | Days |
| Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6 | Topiramate 100 mg | Change at Month 4 | -1.3 | Standard Deviation 3.20 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01081795/results